Compare Surrozen, Inc. with Similar Stocks
Dashboard
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of -51.92% and Operating profit at -274.52% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -27.19
2
Risky -
Stock DNA
Pharmaceuticals & Biotechnology
USD 219 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
3.41
86.05%
-9.29
Revenue and Profits:
Net Sales:
5 Million
(Quarterly Results - Mar 2026)
Net Profit:
-128 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
34.87%
0%
34.87%
6 Months
152.05%
0%
152.05%
1 Year
232.43%
0%
232.43%
2 Years
208.73%
0%
208.73%
3 Years
4942.64%
0%
4942.64%
4 Years
1096.5%
0%
1096.5%
5 Years
212.18%
0%
212.18%
Surrozen, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-51.92%
EBIT Growth (5y)
-274.52%
EBIT to Interest (avg)
-27.19
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-17.70
Sales to Capital Employed (avg)
0.45
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
72.20%
ROCE (avg)
0
ROE (avg)
58.85%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-9.29
EV to EBIT
-3.64
EV to EBITDA
-3.72
EV to Capital Employed
-1.34
EV to Sales
38.42
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Strategic Entities
Domestic Funds
Held in 3 Schemes (4.18%)
Foreign Institutions
Held by 10 Foreign Institutions (1.03%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
5.00
1.00
400.00%
Operating Profit (PBDIT) excl Other Income
-10.40
-9.30
-11.83%
Interest
0.00
0.00
Exceptional Items
-76.90
-55.70
-38.06%
Consolidate Net Profit
-127.50
-27.00
-372.22%
Operating Profit Margin (Excl OI)
-2,091.20%
-9,716.20%
762.50%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 400.00% vs 0.00% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is -372.22% vs -206.82% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
3.50
10.70
-67.29%
Operating Profit (PBDIT) excl Other Income
-41.60
-24.10
-72.61%
Interest
0.00
0.00
Exceptional Items
-203.20
-38.20
-431.94%
Consolidate Net Profit
-242.00
-63.60
-280.50%
Operating Profit Margin (Excl OI)
-12,105.80%
-2,396.90%
-970.89%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -67.29% vs 0.00% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -280.50% vs -47.91% in Dec 2024
About Surrozen, Inc. 
Surrozen, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






